http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2607210-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T428-2982 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 |
| filingDate | 2010-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b630559a0222b90909c470ea7230a54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7186b213431be159b5c0c9a5be28352b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44e6a3b06411e500278a8a174e019459 |
| publicationDate | 2017-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2607210-T3 |
| titleOfInvention | Pharmaceutical composition for inhalation |
| abstract | A method for establishing the fine particle dose (FPD) characteristics of a pharmaceutical composition for inhalation, in which the composition comprises the two active ingredients salmeterol and fluticasone, or pharmaceutically acceptable salts, solvates or esters thereof, and two pharmaceutically acceptable excipients having d50 values of 125-145 μm and 50-100 μm, respectively, in which each of the active ingredients is independently adhered to a different excipient, comprising the steps of: a) providing the two active ingredients and the two pharmaceutically acceptable excipients, in which the d50 values of the individual excipients are 125-145 μm and 50-100 μm; b) form the premixes of an active ingredient and an excipient each; c) mix the two premixes in order to provide the drug fraction; and d) introducing the medicament fraction into a suitable delivery device capable of administering said medicament fraction to the pulmonary system of a patient, characterized in that the establishment of the FPD is carried out by establishing the weight ratio of the excipients used in the two different premixes at a specific value of 1-5. |
| priorityDate | 2009-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.